Treatment of Irritable Bowel Syndrome With Comorbid Anxiety Symptoms With Mirtazapine

被引:12
|
作者
Spiegel, David R. [1 ]
Kolb, Richard [1 ]
机构
[1] Eastern Virginia Med Sch, Dept Psychiat & Behav Sci, Norfolk, VA 23507 USA
关键词
mirtazapine; irritable bowel syndrome; serotonin receptor type-3; anxiety; SEROTONIN TRANSPORTER; PANIC-ATTACKS; ASSOCIATION;
D O I
10.1097/WNF.0b013e318209cef2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Irritable bowel syndrome (IBS) is a functional gastrointestinal tract disorder characterized by recurrent abdominal pain or discomfort, where the onset is associated with either a change in form of stool or its frequency and is often improved with defecation. Alosetron, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, was an effective drug in treating women with diarrhea-predominant IBS. However, the drug was removed from the United States market because of its association with ischemic colitis and serious complications related to severe constipation. Presented here is a case report of a 66-year-old woman with a history of panic disorder and major depression and a 1-year history of IBS-mixed type, which she reported to be "worsened by panic attacks." On the basis that mirtazapine is a potent 5-HT3 receptor antagonist and has demonstrated pain relief from somatic symptoms, we treated our patient with mirtazapine, which seems to have decreased her diarrhea and constipation symptoms, and her psychopathological symptoms.
引用
收藏
页码:36 / 38
页数:3
相关论文
共 50 条
  • [41] Treatment of irritable bowel syndrome
    Hadley, SK
    Gaarder, SM
    AMERICAN FAMILY PHYSICIAN, 2005, 72 (12) : 2501 - 2506
  • [42] THE TREATMENT OF THE IRRITABLE BOWEL SYNDROME
    PAOLAGGI, JA
    FERRANDI, F
    GAZETTE MEDICALE, 1985, 92 (30): : 57 - 61
  • [43] Treatment of irritable bowel syndrome
    Trinkley, K. E.
    Nahata, M. C.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (03) : 275 - 282
  • [44] Generalized anxiety disorder and irritable bowel syndrome
    Ford, A. C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (10) : 1087 - 1088
  • [45] Do comorbid dyspepsia and reflux symptoms affect morbidity, utilization, and outcome in irritable bowel syndrome (IBS)?
    Palsson, OS
    Levy, RL
    Feld, AD
    Von Korff, M
    Drossman, DA
    Turner, MJ
    Whitehead, WE
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S338 - S338
  • [46] Characterising the Gastrointestinal Microbiome in Comorbid Inflammatory Bowel Disease and Irritable Bowel Syndrome
    Shutkever, O. G.
    Taylor, M.
    Wood, H.
    Gracie, D.
    Young, C.
    Hamlin, J.
    Ford, A.
    Quirke, P.
    JOURNAL OF PATHOLOGY, 2017, 241 : S15 - S15
  • [47] Effects of Antidepressants in Patients With Irritable Bowel Syndrome and Comorbid Depression
    Friedrich, Megan
    Grady, Sarah E.
    Wall, Geoffrey C.
    CLINICAL THERAPEUTICS, 2010, 32 (07) : 1221 - 1233
  • [48] RANKING OF SYMPTOMS BY PATIENTS WITH THE IRRITABLE BOWEL SYNDROME
    MAXTON, DG
    MORRIS, JA
    WHORWELL, PJ
    BRITISH MEDICAL JOURNAL, 1989, 299 (6708): : 1138 - 1138
  • [49] Efficacy of acupuncture treatment for diarrhea-predominant irritable bowel syndrome with comorbid anxiety and depression: A meta-analysis and systematic review
    Wang, Zhen
    Hou, Yi
    Sun, Hongwei
    Wang, Zhengwen
    Zhang, Haiyan
    MEDICINE, 2024, 103 (46)
  • [50] Impact of Diet on Symptoms of the Irritable Bowel Syndrome
    Spiller, Robin
    NUTRIENTS, 2021, 13 (02) : 1 - 19